Lantern Pharma Inc. (NASDAQ: LTRN) filed a Current Report on Form 8-K on September 23, 2026, announcing a live webinar to discuss the roadmap for its wholly owned subsidiary, Open-Medicine AI (OMAI). The event is scheduled for today at 12:30 PM Eastern Time.
CEO Panna Sharma will lead the session, joined by the Chief Scientific Officer of Lantern Pharma and the Principal Architect of the multi-agentic platform. The presentation will cover the growth plan for OMAI, which is building a multi-agentic AI platform for end-to-end therapeutic development. The platform was originally commercialized as withZeta.ai in April 2026 for rare and aggressive cancers and later expanded with ZetaOmics, a computational biology module released to early-access users in July 2026.
The webinar will include a live demonstration of the platform's capabilities and a discussion of the following topics:
- Market opportunity: The size of the opportunity and the shift from AI pilots to full-scale adoption in drug development.
- Customers and feedback: User needs, usage patterns, and insights from key customer segments and power users.
- Platform roadmap: Next-generation functionality, priority disease areas, and key milestones, including social and enterprise features.
- Economics: The subscription and enterprise licensing model.
- Benchmarks: Performance metrics and how the platform is being measured.
- Partnerships: Types of collaborations and partnerships currently under discussion.
The event will last 45 minutes, followed by a question-and-answer session. A replay will be made available on the Investors section of the company’s website after the event.
